Vascular Biology |
From the Departments of Laboratory Medicine and Pathobiology and Medicine (E.A., G.H., D.M., M.B.), University of Toronto, Ontario, Canada; the Department of Medicine (U.H.), University of Hamburg, Germany; and the Department of Oral and Developmental Biology (N.F., B.O.), Harvard Medical School, Boston, Mass.
Correspondence to Michelle Bendeck, Department of Laboratory Medicine and Pathobiology, University of Toronto, 1 Kings College Circle, Room 6217, Toronto, Ontario, Canada M5S 1A8. E-mail michelle.bendeck{at}utoronto.ca
| Abstract |
|---|
|
|
|---|
Methods and Results Type VIII collagen was upregulated after wounding of WT SMCs. KO SMCs exhibited greater adhesion to type I collagen than WT SMCs (optical density [OD595]=0.458±0.044 versus 0.193±0.071). By contrast, the WT SMCs spread more (389±75% versus 108±14% increase in cell area), migrated further (total distance 80.6±6.2 µm versus 64.2±4.4 µm), and exhibited increased [3H]-thymidine uptake (160 000±22 300 versus 63 100±12 100 counts per minute) when compared with KO SMCs. Gelatin zymograms showed that WT SMCs expressed latent matrix metalloproteinase 2, whereas KO SMCs did not. Addition of exogenous type VIII collagen returned levels of KO SMC adhesion (OD595=0.316±0.038), migration (79.5±5.8 µm), and latent matrix metalloproteinase 2 expression to levels comparable to WT SMCs.
Conclusions This study suggests that SMCs can modify the matrix microenvironment by producing type VIII collagen, using it to overlay type I collagen, and generating a substrate favorable for migration.
Type VIII collagen is upregulated after vascular injury and in atherosclerosis. Using smooth muscle cells from wild-type and type VIII collagen knockout mice, we show that cells that are able to produce endogenous type VIII collagen, proliferate, spread, and migrate more when the cells are plated on a type I collagen matrix.
Key Words: atherosclerosis restenosis collagen smooth muscle cell migration MMP
| Introduction |
|---|
|
|
|---|
Type VIII collagen is a member of the short chain collagen family, composed of
1 (VIII) and
2 (VIII) chains. It is produced by corneal and aortic endothelial cells, as well as mesangial cells, and is upregulated during the proliferation of these cells and during angiogenesis.58 In normal arteries, it has been localized to the subendothelial intima and is present in very low amounts in the media and adventitia.9 Type VIII collagen expression is dramatically increased after balloon injury of the rat carotid10,11 or the porcine coronary artery.12 In the rat balloon injury model, type VIII collagen was expressed by SMCs migrating and proliferating during intimal thickening.10,11 It is also present in the atherosclerotic lesions of apolipoprotein Edeficient mice13 and cholesterol-fed rabbits subject to balloon injury,14 where expression is localized to intimal SMCs and to macrophage-rich areas of the plaque, suggesting that macrophages also produce type VIII collagen. Type VIII collagen was similarly localized in human atherosclerotic plaques.1517 Expression of mRNA for type VIII collagen is regulated by platelet-derived growth factor, fibroblast growth factor 2, and angiotensin II, all important factors in the pathogenesis of atherosclerosis.11,18
Investigating the interaction of SMCs with exogenous type VIII collagen in vitro, we and others have shown that the protein acts as an attachment and chemotactic factor for SMCs.11,18 SMCs attach to type VIII collagen, but it is a less adhesive substrate and promotes greater cell migration than type I collagen. In addition, type VIII collagen stimulates SMC matrix metalloproteinase synthesis, whereas type I collagen does not.18 These studies were performed using exogenous type VIII collagen coated on tissue culture plates as a substrate for the SMCs. However, in the diseased vessel wall, type VIII collagen is expressed and deposited by SMCs in the presence of an existing matrix rich in type I collagen. The function of endogenously expressed type VIII collagen in this more complex matrix microenvironment has not been studied. We now hypothesize that after arterial injury, SMCs produce type VIII collagen and use it to overlay an existing extracellular matrix, providing a substrate more favorable for rapid migration. To address this hypothesis, we have compared aortic SMCs isolated from Col8a1+/+/Col8a2+/+ mice [wild-type (WT)] to SMCs isolated from type VIII collagendeficient mice, Col8a1//Col8a2/ (KO), to examine different components of the migratory process when the cells are plated on either uncoated or type I collagencoated surfaces.
| Methods |
|---|
|
|
|---|
Mice with targeted deletion of both the Col8a1 and Col8a2 genes (KO) were generated in the laboratory of Bjorn Olsen (Harvard Medical School) as described19 with WT littermate mice used as controls. Aortic vascular SMCs were isolated from the mice as described previously.20 For all of the experiments, tissue culture plates/flasks were either left uncoated or coated with a solution containing 50 µg/mL of pepsin-solubilized bovine dermal type I collagen (Vitrogen 100; Collagen Biomaterials). Cell attachment assays were performed as described previously.18 For spreading assays, 100 000 cells were seeded onto 25-cm2 tissue culture flasks and imaged using a Nikon Eclipse TE200 inverted microscope equipped with a heated stage. A Hamamatsu digital camera (model #C474295) was used to capture images every 10 minutes for 4 hours after plating. Three to 6 cells were analyzed for each experiment. Migration assays were similar, with the following modifications: 100 000 cells/well were seeded onto 6-well plates, then grown until 50% confluence (0.5 to 2 days), and, subsequently, images of migrating cells were captured every 10 minutes for 8 hours. Six to 8 cells were analyzed in each experiment. SMC proliferation was estimated using [3H]-thymidine incorporation. MMP activity in the SMC-conditioned medium was assayed using gelatin zymograms as described previously.18 Rescue experiments using KO SMCs with the addition of exogenous type VIII collagen were also performed. Wells were first coated with a solution containing 37.5 µg/mL type I collagen/PBS then rinsed with PBS and coated with 6.6 µg/mL exogenous type VIII collagen/PBS (type VIII collagen was isolated from bovine Descemets membrane as described previously21). This gives a coating composed of 75% type I collagen and 25% type VIII collagen, with the same total molar concentration as the 50 µg/mL type I collagen used in the first experiments. Adhesion and migration experiments were performed on this mixed collagen substrate as described above. Immunocytochemistry was done using an anticollagen
1 (VIII) monoclonal antibody (Clone 8C, Seikagaku America).
| Results |
|---|
|
|
|---|
0.001) and rounder (0.153±0.021 versus 0.112±0.008; P=0.039, with a value of 1 corresponding to a perfect circle) than WT SMCs. KO SMCs plated on polymerized type I collagen exhibited a similar morphology to those plated on plastic, whereas WT SMCs plated on type I collagen were more rounded with no protrusions visible (data not shown). There was no difference in viability between KO and WT SMCs, whether they were plated on uncoated or on type I collagen-coated wells (data not shown).
Production of Type VIII Collagen Was Upregulated After Injury
Confluent layers of SMCs were subject to a scrape wound, then immunostained with an antibody against type VIII collagen. Immediately after wounding, WT SMCs in the uninjured monolayer and in areas adjacent to the wound stained for type VIII collagen (Figure 1A), whereas KO SMCs did not stain (Figure 1B). Type VIII collagen was localized in the cytoplasm with a punctate staining pattern. Double staining with an antibody raised against a marker of the Golgi complex (58K Golgi protein marker) revealed that most of the intracellular type VIII collagen was localized in the Golgi (data not shown). A substantial increase in type VIII collagen was evident in the WT cells 24 hours after wounding (Figure 1C). By contrast, KO SMCs did not stain for type VIII collagen at 24 hours (Figure 1D).
|
We had some difficulty staining type VIII collagen within the extracellular matrix, probably because the protein is tightly complexed with other matrix proteins. However, after lightly digesting the matrix with 10 µg/mL pepsin in 0.1 mol/L acetic acid, we were able to detect extracellular immunostaining for type VIII collagen (Figure 2A). Furthermore, after treating confluent cultures with a mixture of EDTA/EGTA to lift off cells, then lysing the underlying matrix, we were able to detect matrix-bound type VIII collagen produced by WT cells but not KO cells on a Western blot (Figure 2B).
|
Production of Type VIII Collagen Decreased Attachment of SMCs to Type I Collagen and Facilitated Spreading and Migration
SMCs must attach to substrate to gain traction for migration; however, too strong an attachment may fix the cells in place and prevent migration. To determine the effect of type VIII collagen production on SMC adhesion, we measured adhesion to uncoated wells or to wells coated with type I collagen. The WT SMCs adhered significantly less than KO SMCs to uncoated wells (Figure 3A) or to wells coated with type I collagen (Figure 3B). The difference in adhesion was especially large when the cells were plated on type I collagen (optical density [OD595]=0.193±0.071 for WT cells versus OD595=0.458±0.044 for KO cells). The addition of exogenous type VIII collagen to the wells to rescue the phenotype resulted in the decreased attachment of KO cells (OD595=0.316±0.038) to a level that was not significantly different from WT cells (Figure 3B).
|
Cell spreading and protrusion occur during migration and are also affected by adhesion strength, so we compared the spreading in WT and KO SMCs. Our preliminary experiments revealed that most spreading occurred during the first hour after plating. When plated on uncoated flasks, WT SMCs spread and increased cell area by &4-fold in 1 hour (370±61%), significantly more than KO SMCs, which increased in area by only 2-fold (206±37%; Figure 4A). WT SMCs also spread &4-fold in 1 hour when plated on 50 µg/mL type I collagen (389±75%), significantly more than KO SMCs, which did not spread on type I collagen (108±14%; Figure 4B).
|
We used time-lapse microscopy to measure cell migration. The total distance migrated by individual cells over an 8-hour period was calculated. Whether plated on uncoated or type I collagencoated wells, the distance traveled by WT SMCs was significantly greater than that for KO SMCs (Figure 5). When plated on uncoated wells, WT SMCs traveled a total distance of 115±9 µm compared with 72.7±3.8 µm for KO SMCs (Figure 5A). When plated on 50 µg/mL type I collagen, WT SMCs traveled a total distance of 80.6±6.2 µm compared with 64.2±4.4 µm for KO SMCs (Figure 5B). The addition of type VIII collagen to the plates rescued the KO SMC migration such that the KO rescue (KO-R) SMCs traveled a distance not different from the distance traveled by WT SMCs (79.5±5.8 µm; Figure 5B).
|
Type VIII Collagen Production Increases MMP Activity
Because MMPs facilitate migration of SMCs by allowing the clearance of matrix barriers, gelatin zymograms were used to measure MMP-2 and MMP-9 activity in conditioned media from WT and KO SMCs (Figure 6A). Conditioned media from mouse embryonic fibroblasts (MEFs) was used as a positive control and to identify the lytic bands on zymogram gels. MEF-conditioned media contained distinct lytic bands at 95 kDa (active MMP-9), 70 kDa (latent MMP-2), and 61 kDa (active MMP-2). Media from WT and KO mouse SMCs contained lytic bands of 106 kDa (latent MMP-9), 95 kDa (active MMP-9), 84 kDa (unknown), 77 kDa (unknown), and 70 kDa (latent MMP-2). There was increased lysis in the latent MMP-2 band in the conditioned media of WT SMCs compared with the conditioned media of KO SMCs. The addition of exogenous type VIII collagen to the plate led to an increase in latent MMP-2 production by KO cells, showing a complete rescue of the KO phenotype. By contrast, there were no apparent differences in the activity of MMP-9 or the unidentified bands, comparing WT and KO SMCs. Within each cell type, there were no differences in MMP activity between cells plated on plastic or on type I collagen (data not shown).
|
Type VIII Collagen Facilitates SMC Proliferation
To assess cell proliferation, [3H]-thymidine incorporation was measured. Thymidine incorporation was similar in WT and KO SMCs plated on plastic (Figure 6B). By contrast, thymidine uptake was increased in WT SMCs plated on type I collagen (160 000±22 300 counts per minute) compared with KO SMCs (63 100±12 100 counts per minute).
| Discussion |
|---|
|
|
|---|
However, the vascular extracellular matrix is a complex mixture composed of several different types of molecules, and it is particularly rich in type I collagen. In fact, type I collagen and type VIII collagen are both upregulated and colocalized during plaque development.14 In vitro studies have shown that SMCs can attach to type I collagen; nonetheless, a substantial body of evidence shows that intact polymerized type I collagen inhibits cell migration and proliferation and downregulates the expression of many genes.24 By contrast, type VIII collagen appears to stimulate opposite responses. Although the effects of exogenous type VIII collagen on SMCs have been studied, the importance of endogenously produced type VIII collagen is not known. Furthermore, the effect of type VIII collagen in the presence of a polymerized type I collagen matrix has not been examined. In the current study, we hypothesized that SMCs produce type VIII collagen, lay it down on top of type I collagen, and use this modified, less adhesive matrix to facilitate migration. To investigate this, we studied SMCs harvested from the aortas of WT and type VIII collagen KO mice. We compared the ability of these cells to migrate on dishes coated with polymerized type I collagen, which was used to mimic the natural environment encountered in the vascular media.
KO SMCs displayed significantly stronger attachment than WT SMCs to both tissue culture plastic and to wells coated with type I collagen substrate. This suggests that cells that are able to produce type VIII collagen adhere less, and these results are in accordance with our previous studies where we found that SMC attachment to type VIII collagen was less than attachment to type I collagen.18 In fact, when KO SMCs were plated on a mixture of type VIII and type I collagen, their levels of attachment were reduced to a level comparable to WT SMCs, showing a partial rescue of the KO phenotype.
To accomplish migration in a defined direction, cells first extend leading lamellopodia, which attach to the substrate. After this is cell contraction, then attachments to the substrate at the rear of the cell are broken, allowing tail retraction and forward translocation of the cell body.22,23 The ability to spread and subsequently migrate depends on a critical value of adhesive strength between cell and substrate: high or low levels of substrate attachment inhibit spreading and migration, whereas maximum migration occurs at intermediate adhesion strengths.24 We found that WT SMCs migrated a greater distance than KO SMCs on both uncoated and type I collagen-coated wells. This suggests that the ability to produce type VIII collagen allowed the cells to overcome strong adhesion to type I collagen and, thus, enabled migration. The WT SMCs extruded well-defined protrusions and translocated efficiently on the substrate. By contrast, the KO cells displayed membrane ruffling with repeated extensions and retractions of stellate processes in all directions. Importantly, we were able to rescue KO SMC migration by adding exogenous type VIII collagen to the wells. Interestingly, Rocnik et al25 reported that new collagen synthesis is required for SMC migration on polymerized type I collagen. They did not identify the type of collagen produced; however, we can speculate that it is type VIII collagen.
Another important difference was that WT cells exhibited higher proliferation rates than KO cells when plated on type I collagen. This suggests that endogenously produced type VIII collagen allows cells to overcome the inhibitory effects of type I collagen on proliferation. Likewise, type VIII collagen has recently been implicated in stimulation of the proliferation of corneal endothelial cells.19,26 The production of matrix-degrading enzymes, such as the MMPs, is required for SMCs to detach from matrix to migrate or proliferate and to facilitate the clearance of matrix barriers. Gelatin zymograms revealed MMP-2 activity in the media from WT SMCs, whereas there was less MMP-2 activity in the media from the KO SMCs. However, the addition of exogenous type VIII collagen to the KO SMCs increased the MMP-2 production by these cells. These results confirm previous studies where we showed that type VIII collagen stimulated the production of both MMP-2 and MMP-9 by rat SMCs.18 However, we did not see a difference in MMP-9 activity in the mouse cells, suggesting that there may be species-specific differences.
Type VIII collagen interacts with SMCs via the
1ß1 and
2ß1 integrins18 and the recently discovered discoidin domain receptor tyrosine kinases (DDR1 and 2).20 Both integrins and DDR1 control cell proliferation on collagenous substrates and can activate intracellular signaling pathways leading to the upregulation of MMPs.18,2732 Furthermore, both DDR1,20 and the
1ß1 integrin33 are upregulated after arterial injury in coincidence with type VIII collagen.
Our studies have concentrated on the SMC as the source of type VIII collagen and focused on SMC interactions with this protein. However, other cell types in the vessel wall produce type VIII collagen in the atherosclerotic plaque, including endothelial cells5 and macrophages.15 At this time, very little is known about the interactions of these cells with the protein, but these interactions are also likely to be important in mediating the injury response in vascular disease.
The results presented here show that vascular SMCs derived from mice with targeted deletion of type VIII collagen exhibit critical defects in migration and proliferation. Furthermore, the ability of these cells to express MMP-2 is reduced compared with WT SMCs, which produce type VIII collagen. This reduction in MMP-2 activity and migration over a type I collagen matrix was reversed with the addition of exogenous type VIII collagen. These studies suggest that SMCs are able to produce type VIII collagen and use it to overlay type I collagen, providing a provisional substrate favorable for migration. Thus, type VIII collagen may be an important mediator of SMC responses in vascular diseases that involve cell migration, including atherosclerosis, restenosis, vein graft, and transplant atherosclerosis.
| Acknowledgments |
|---|
Received April 7, 2005; accepted October 19, 2005.
| References |
|---|
|
|
|---|
1-VIII collagen is expressed in the rat glomerulus and in resident glomerular cells. Am J Physiol. 1993; 264: F1003F1010.
1 type VIII collagen in injured, platelet-derived growth factor-BB stimulated rat carotid arteries. Circ Res. 1996; 79: 524531.
1ß1 mediates a unique collagen-dependent proliferation pathway in vivo. J Cell Biol. 1998; 142: 587594.
1ß1 integrin is expressed during neointima formation in rat arteries and mediates collagen matrix reorganization. J Clin Invest. 1996; 97: 24692477.[Medline]
[Order article via Infotrieve]This article has been cited by other articles:
![]() |
H. Qiu, C. Depre, K. Ghosh, R. G. Resuello, F. F. Natividad, F. Rossi, A. Peppas, Y.-T. Shen, D. E. Vatner, and S. F. Vatner Mechanism of Gender-Specific Differences in Aortic Stiffness With Aging in Nonhuman Primates Circulation, August 7, 2007; 116(6): 669 - 676. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Qiu, B. Tian, R. G. Resuello, F. F. Natividad, A. Peppas, Y.-T. Shen, D. E. Vatner, S. F. Vatner, and C. Depre Sex-specific regulation of gene expression in the aging monkey aorta Physiol Genomics, April 24, 2007; 29(2): 169 - 180. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. T. Gerthoffer Mechanisms of Vascular Smooth Muscle Cell Migration Circ. Res., March 16, 2007; 100(5): 607 - 621. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |